NeuroPace Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares

Core Viewpoint - NeuroPace, Inc. has successfully completed a public offering of 7,475,000 shares at a price of $10.00 per share, raising approximately$74.8 million in gross proceeds [1][2] Group 1: Offering Details - The offering included 975,000 shares sold due to the underwriters' full exercise of their option to purchase additional shares [1] - The net proceeds will be used primarily to repurchase 5,270,845 shares from significant stockholder KCK Ltd. at $9.40 per share [2] - Remaining proceeds will be allocated for general corporate purposes, including clinical trials, research and development, and working capital [2] Group 2: Management and Registration - J.P. Morgan, Cantor, Wells Fargo Securities, and Leerink Partners served as joint book-running managers for the offering, with Lake Street Capital Markets as the lead manager [3] - The shares were offered under a shelf registration statement effective since November 22, 2022, with a final prospectus supplement filed with the SEC [4] Group 3: Company Overview - NeuroPace is a medical device company focused on improving the lives of individuals with epilepsy through its RNS System, which provides personalized, real-time treatment [6]